| Budget Amount *help |
¥15,860,000 (Direct Cost: ¥12,200,000、Indirect Cost: ¥3,660,000)
Fiscal Year 2019: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed the clinical and pathophysiological aspects of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease,(MOGAD).1) Clinical features of MOGAD cases were similar in Japanese and Western cases.2) We identified two types of MOG-antibody-associated cerebral cortical encephalitis (1.unilateral cerebral cortical lesion with epilepsy and 2.bilateral medial frontal cortical lesions with paraplegia). 3)Neuropathological study of MOGAD revealed that perivenous demyelination is the feature of the disease and MOG staining was preferentially lost in comparison with other myelin proteins, and the infiltrating lymphocytes were mainly CD4+. These findings indicated that MOGAD is an entity distinct from multiple sclerosis and aquaporin-4-antibody-positive neuromyelitis optica spectrum disorders.
|
